Sign up
Pharma Capital

PureTech Health affiliate resTORbio raises another US$40mln as age-related trial progresses

The funding brings equity investment in resTORbio so far this year to US$65mln
picture of elderly
TORC1 is a key pathway involved in aging

PureTech Health PLC (LON:PRTC) affiliate resTORbio has raised US$40mln through an oversubscribed funding run led by OrbiMed.

Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio took part and the funding brings equity investment in resTORbio so far this year to US$65mln.

 Daphne Zohar, chief executive, said she was extremely pleased with the progress made by resTORbio, which has a programme for aging-related diseases and conditions that selectively targets TORC1, a key pathway involved in aging.

A Phase 2b clinical study is underway and designed to assess its safety, tolerability and efficacy reducing respiratory tract infections (RTIs) in the elderly.

Top-line results are expected in the second half of 2018.  


Register here to be notified of future PRTC Company articles
View full PRTC profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.